Healthequity (NASDAQ:HQY) announced its quarterly earnings data on Tuesday. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.13 by $0.04, Briefing.com reports. Healthequity had a net margin of 20.27% and a return on equity of 13.93%. The business had revenue of $56.80 million during the quarter, compared to the consensus estimate of $55.27 million. During the same period in the previous year, the business earned $0.10 earnings per share. The company’s revenue was up 31.0% on a year-over-year basis.

Shares of Healthequity (NASDAQ HQY) traded down $0.37 on Tuesday, reaching $48.49. 516,436 shares of the company’s stock were exchanged, compared to its average volume of 522,736. Healthequity has a twelve month low of $37.62 and a twelve month high of $55.31. The company has a market capitalization of $2,950.00, a PE ratio of 81.68, a P/E/G ratio of 2.26 and a beta of 1.74.

In related news, Director Frank Medici sold 316,644 shares of the company’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $51.96, for a total value of $16,452,822.24. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Berkley Capital, Llc sold 700 shares of the company’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $52.05, for a total transaction of $36,435.00. The disclosure for this sale can be found here. Insiders have sold 1,743,212 shares of company stock worth $91,090,651 in the last quarter. Company insiders own 19.00% of the company’s stock.

A number of research firms have weighed in on HQY. Zacks Investment Research cut shares of Healthequity from a “buy” rating to a “hold” rating in a research note on Wednesday, November 15th. BidaskClub raised shares of Healthequity from a “sell” rating to a “hold” rating in a research note on Tuesday, November 7th. Cantor Fitzgerald reissued a “buy” rating and issued a $56.00 price objective on shares of Healthequity in a research note on Monday, September 25th. Robert W. Baird reissued a “hold” rating on shares of Healthequity in a research note on Thursday, September 21st. Finally, Oppenheimer reaffirmed a “buy” rating and set a $61.00 price target on shares of Healthequity in a research report on Wednesday, September 6th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Healthequity has a consensus rating of “Buy” and a consensus target price of $57.50.

WARNING: This report was posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/healthequity-hqy-issues-quarterly-earnings-results/1746205.html.

About Healthequity

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Earnings History for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.